Table I.
Clinical management of MCRC patients after progression to first-line FIr-B/FOx regimen.
| Overall
|
KRAS genotype
|
||
|---|---|---|---|
| No. of patients (%) | Wild-type (%) | Mutant (%) | |
| Total no. | 54 | 26 | 25 |
| Second line treatment | 40 (74.1) | 21 (80.8) | 17 (68) |
| Medical treatment | 36 (66.7) | 18 (69.2) | 16 (64) |
| Triplet chemotherapy plus targeted agent | 10 (18.5) | 5 (19.2) | 5 (20) |
| Triplet chemotherapy plus bevacizumab | 7 | 3 | 4 |
| Triplet chemotherapy plus cetuximab | 3 | 2 | 1 |
| Triplet regimen | 19 (35.2) | 10 (38.5) | 7 (28) |
| Doublet chemotherapy plus bevacizumab | 5 | 1 | 4 |
| Doublet chemotherapy plus cetuximab | 13 | 8 | 3 |
| Triplet chemotherapy | 1 | 1 | - |
| Doublet regimen | 3 (5.6) | 2 (7.6) | 1 (4) |
| Mono-chemotherapy plus bevacizumab | 3 | 2 | 1 |
| Mono therapy | 4 (7.4) | 1 (3.8) | 3 (12) |
| Mono-chemotherapy | 3 | - | 3 |
| Panitumumab | 1 | 1 | - |
| Surgery | 4 (7.4) | 3 (11.5) | 1 (4) |
| Death events without further treatment | 14 (25.9) | 5 (19.2) | 8 (32) |